Mavorixafor
CAS 558447-26-0Small Molecule
Overview
Mavorixafor is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL518924).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Mavorixafor expires 11 Dec 2038 and exclusivity 26 Apr 2031. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
- Canonical SMILES
- C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
- InChIKey
- WVLHHLRVNDMIAR-IBGZPJMESA-N
Verified Supplier Partner
Do you supply Mavorixafor? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.